Alto Neuroscience, Inc. Basic Shares Outstanding (Weighted Average)
Alto Neuroscience, Inc. (ANRO) reported Basic Shares Outstanding (Weighted Average) of 42.81 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-12
- Alto Neuroscience, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 42.81M shares, a 58.14% increase year-over-year.
- Alto Neuroscience, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 32.89M shares, a 21.61% increase year-over-year.
- Alto Neuroscience, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 34.18M shares, a 27.67% increase year-over-year.
- Alto Neuroscience, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 27.10M shares, a 0.54% increase year-over-year.
- Alto Neuroscience, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 28.85M shares, a 17.28% increase from fiscal 2024.
- Alto Neuroscience, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 24.60M shares, a 559.39% increase from fiscal 2023.
- Alto Neuroscience, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 3.73M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 42.81M shares 10-Q · filed 2026-08-12 | 40.18M shares 10-Q · filed 2026-08-12 | 36.63M shares derived: average of 3 quarters · filed 2026-08-12 | 34.25M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 32.89M shares 10-Q · filed 2026-05-13 | 33.54M shares derived: average of 2 quarters · filed 2026-05-13 | 31.39M shares derived: average of 3 quarters · filed 2026-05-13 | 30.31M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | 34.18M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 30.64M shares derived: average of 2 quarters · filed 2026-03-16 | 29.45M shares derived: average of 3 quarters · filed 2026-08-12 | 28.85M shares 10-K · filed 2026-03-16 |
| 2025-09-30 | 27.10M shares 10-Q · filed 2025-11-12 | 27.09M shares derived: average of 2 quarters · filed 2026-08-12 | 27.07M shares 10-Q · filed 2025-11-12 | 27.00M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | 27.07M shares 10-Q · filed 2026-08-12 | 27.06M shares 10-Q · filed 2026-08-12 | 26.96M shares derived: average of 3 quarters · filed 2026-08-12 | 26.96M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | 27.05M shares 10-Q · filed 2026-05-13 | 26.91M shares derived: average of 2 quarters · filed 2026-05-13 | 26.93M shares derived: average of 3 quarters · filed 2026-05-13 | 26.92M shares derived: average of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | 26.77M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 26.87M shares derived: average of 2 quarters · filed 2026-03-16 | 26.88M shares derived: average of 3 quarters · filed 2026-03-16 | 24.60M shares 10-K · filed 2026-03-16 |
| 2024-09-30 | 26.96M shares 10-Q · filed 2025-11-12 | 26.94M shares derived: average of 2 quarters · filed 2025-11-12 | 23.88M shares 10-Q · filed 2025-11-12 | 18.81M shares derived: average of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | 26.91M shares 10-Q · filed 2025-08-13 | 22.31M shares 10-Q · filed 2025-08-13 | 16.10M shares derived: average of 3 quarters · filed 2025-08-13 | 13.01M shares derived: average of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | 17.60M shares 10-Q · filed 2025-05-14 | 10.69M shares derived: average of 2 quarters · filed 2025-05-14 | 8.37M shares derived: average of 3 quarters · filed 2025-05-14 | 7.21M shares derived: average of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | 3.77M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 3.76M shares derived: average of 2 quarters · filed 2025-03-20 | 3.74M shares derived: average of 3 quarters · filed 2025-03-20 | 3.73M shares 10-K · filed 2025-03-20 |
| 2023-09-30 | 3.74M shares 10-Q · filed 2024-11-12 | 3.73M shares derived: average of 2 quarters · filed 2024-11-12 | 3.72M shares 10-Q · filed 2024-11-12 | |
| 2023-06-30 | 3.72M shares 10-Q · filed 2024-08-13 | 3.70M shares 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | 3.69M shares 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |